| 1 |
1
하기 화학식 1 또는 2로 표시되는 화합물, 이의 이성질체, 또는 이의 약학적으로 허용가능한 염 :[화학식 1][화학식 2]화학식 1에서 X 및 Y는 각각 독립적으로 질소(N), 황(S), 또는 산소(O)이고, Z는 산소(O), 또는 수소 하나가 치환된 탄소(C)이고,R1 은 페닐, 5 또는 6원의 헤테로아릴, 또는 8 내지 12원의 바이헤테로아릴이 고, 상기 헤테로아릴 및 바이헤테로아릴은 고리 내 N, S, 및 O 중 1개 이상을 포함 하며, 상기 R1 은 치환되지 않거나, 할로겐, 수산화기, 아민기, 시아노기, 알콕시기, 니트로기, 또는 트리플로오로메틸기로 치환될 수 있으며,m은 1 또는 2이고, n은 0 내지 3의 정수이며;화학식 2에서 X 및 Y는 각각 독립적으로 질소(N), 황(S), 또는 산소(O)이고, Z는 산소(O), 또는 수소 하나가 치환된 탄소(C)이고,R1 은 플루오로페닐(fluorophenyl) 또는 페닐(phenyl)이고,R1 이 페닐인 경우, X 내지 Z 중 하나가 산소(O)이고,n은 2 또는 3의 정수임
|
| 2 |
2
제1항에 있어서, 상기 화학식 1에서, R1 은 플루오로페닐(fluorophenyl), 페닐(phenyl), 1H-인돌-3-일(1H-indol-3-yl), 4-메톡시페닐(4-methoxyphenyl), 4-(트리플루오로메틸)페닐(4-(trifluoromethyl)phenyl), 4-아미노페닐(4-aminophenyl), 4-하이드록시페닐(4-hydroxyphenyl), 3,4-디메톡시페닐(3,4-dimethoxyphenyl), 4-브로모페닐(4-bromophenyl), 3-플루오로페닐(3-fluorophenyl), 3,4,5-트리메톡시페닐(3,4,5-trimethoxyphenyl), 3,4-디플루오로페닐(3,4-difluorophenyl), 4-클로로페닐(4-chlorophenyl),4-시아노페닐(4-cyanophenyl), 3,4-디하이드록시페닐(3,4-dihydroxyphenyl), 4-나이트로페닐(4-nitrophenyl), 3,4,5-트리하이드록시페닐(3,4,5-trihydroxyphenyl), 퓨란-2-일(furan-2-yl), 또는 티오펜-2-일(thiophen-2-yl)인 것을 특징으로 하는 화합물, 이의 이성질체, 또는 이의 약학적으로 허용 가능한 염
|
| 3 |
3
제2항에 있어서, 상기 화합물은 하기 화합물들로 이루어진 군으로부터 선택되는 것을 특징으로 하는 화합물, 이의 이성질체, 또는 이의 약학적으로 허용가능한 염 :3-(3-(4-fluorophenethyl)-1,2,4-oxadiazol-5-yl)-N-hydroxypropanamide (화합물1) ;(E)-3-(3-(4-fluorostyryl)-1,2,4-oxadiazol-5-yl)-N-hydroxypropanamide (화합물2) ;N-hydroxy-3-(3-phenethyl-1,2,4-oxadiazol-5-yl)propanamide (화합물3) ;(E)-N-hydroxy-3-(3-styryl-1,2,4-oxadiazol-5-yl)propanamide (화합물4) ;4-(3-(4-fluorophenethyl)-1,2,4-oxadiazol-5-yl)-N-hydroxybutanamide (화합물5) ;(E)-4-(3-(4-fluorostyryl)-1,2,4-oxadiazol-5-yl)-N-hydroxybutanamide (화합물6) ;N-hydroxy-4-(3-phenethyl-1,2,4-oxadiazol-5-yl)butanamide (화합물7) ;(E)-N-hydroxy-4-(3-styryl-1,2,4-oxadiazol-5-yl)butanamide (화합물8) ;3-(2-((1H-indol-3-yl)methyl)thiazol-4-yl)-N-hydroxypropanamide (화합물9) ;3-(2-benzyloxazol-4-yl)-N-hydroxypropanamide (화합물10) ;N-hydroxy-3-(2-phenethyloxazol-4-yl)propanamide (화합물11) ;(E)-N-hydroxy-3-(2-styryloxazol-4-yl)propanamide (화합물12) ;3-(2-(2-(1H-indol-3-yl)ethyl)oxazol-4-yl)-N-hydroxypropanamide (화합물13) ;4-(2-benzyloxazol-4-yl)-N-hydroxybutanamide (화합물15) ;4-(2-((1H-indol-3-yl)methyl)oxazol-4-yl)-N-hydroxybutanamide (화합물16) ;N-hydroxy-4-(2-phenethyloxazol-4-yl)butanamide (화합물17) ;4-(2-(2-(1H-indol-3-yl)ethyl)oxazol-4-yl)-N-hydroxybutanamide (화합물18) ;(E)-N-hydroxy-4-(2-styryloxazol-4-yl)butanamide (화합물19) ;2-(4-fluorophenethyl)-N-hydroxythiazole-4-carboxamide (화합물21) ;2-(2-(4-fluorophenethyl)thiazol-4-yl)-N-hydroxyacetamide (화합물23) ;3-(2-benzylthiazol-4-yl)-N-hydroxypropanamide (화합물25) ;3-(2-((1H-indol-3-yl)methyl)thiazol-4-yl)-N-hydroxypropanamide (화합물26) ;N-hydroxy-3-(2-phenethylthiazol-4-yl)propanamide (화합물27) ;3-(2-(2-(1H-indol-3-yl)ethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물29) ;3-(2-(4-fluorophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물31) ;(E)-3-(2-(4-fluorostyryl)thiazol-4-yl)-N-hydroxypropanamide (화합물32) ; N-hydroxy-3-(2-(4-methoxyphenethyl)thiazol-4-yl)propanamide (화합물33) ;N-hydroxy-3-(2-(4-(trifluoromethyl)phenethyl)thiazol-4-yl)propanamide (화합물34) ;3-(2-(4-aminophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물35) ;N-hydroxy-3-(2-(4-hydroxyphenethyl)thiazol-4-yl)propanamide (화합물36) ;3-(2-(3,4-dimethoxyphenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물37) ;3-(2-(4-bromophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물38) ;3-(2-(3-fluorophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물39) ;N-hydroxy-3-(2-(3,4,5-trimethoxyphenethyl)thiazol-4-yl)propanamide (화합물40) ;3-(2-(3,4-difluorophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물41) ;3-(2-(4-chlorophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물42) ;3-(2-(4-cyanophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물43) ;3-(2-(3,4-dihydroxyphenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물44) ;N-hydroxy-3-(2-(4-nitrophenethyl)thiazol-4-yl)propanamide (화합물45) ;N-hydroxy-3-(2-(3,4,5-trihydroxyphenethyl)thiazol-4-yl)propanamide (화합물46) ;3-(2-(2-(furan-2-yl)ethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물47) ;N-hydroxy-3-(2-(2-(thiophen-2-yl)ethyl)thiazol-4-yl)propanamide (화합물48) ;4-(2-benzylthiazol-4-yl)-N-hydroxybutanamide (화합물49) ;4-(2-((1H-indol-3-yl)methyl)thiazol-4-yl)-N-hydroxybutanamide (화합물50) ;N-hydroxy-4-(2-phenethylthiazol-4-yl)butanamide (화합물51) ;4-(2-(2-(1H-indol-3-yl)ethyl)thiazol-4-yl)-N-hydroxybutanamide (화합물53) ;4-(2-(4-fluorophenethyl)thiazol-4-yl)-N-hydroxybutanamide (화합물55) ; 및 (E)-4-(2-(4-fluorostyryl)thiazol-4-yl)-N-hydroxybutanamide (화합물56)
|
| 4 |
4
제1항에 있어서, 상기 화학식 1 또는 2에서 R1은 플루오로페닐(fluorophenyl) 것을 특징으로 하는 화합물, 이의 이성질체, 또는 이의 약학적으로 허용가능한 염
|
| 5 |
5
제 4항에 있어서, 하기 화합물들로 이루어진 군으로부터 선택되는 것을 특징으로 하는 화합물, 이의 이성질체, 또는 이의 약학적으로 허용가능한 염 :3-(3-(4-fluorophenethyl)-1,2,4-oxadiazol-5-yl)-N-hydroxypropanamide (화합물1) ;(E)-3-(3-(4-fluorostyryl)-1,2,4-oxadiazol-5-yl)-N-hydroxypropanamide (화합물2) ;2-(4-fluorophenethyl)-N-hydroxythiazole-4-carboxamide (화합물21) ;2-(2-(4-fluorophenethyl)thiazol-4-yl)-N-hydroxyacetamide (화합물23) ;3-(2-(4-fluorophenethyl)thiazol-4-yl)-N-hydroxypropanamide (화합물31) ;(E)-3-(2-(4-fluorostyryl)thiazol-4-yl)-N-hydroxypropanamide (화합물32) ; 및(E)-4-(2-(4-fluorostyryl)thiazol-4-yl)-N-hydroxybutanamide (화합물56)
|
| 6 |
6
제5항에 있어서, (E)-3-(2-(4-fluorostyryl)thiazol-4-yl)-N-hydroxypropanamide (화합물32), 이의 이성질체, 또는 이의 약학적으로 허용가능한 염
|
| 7 |
7
제1항 내지 제6항 중 어느 한 항의 화합물, 이의 이성질체, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 치매 또는 인지장애 예방 또는 치료용 약학적 조성물
|
